Acetyl Tetrapeptide-5 Evidence Guide
Evidence for Acetyl Tetrapeptide-5 is too preliminary to support a research protocol with confidence. All evidence comes from a single manufacturer-funded study on periorbital edema reduction. Independent replication does not exist. This compound should not be selected over better-evidenced cosmetic peptides.
Our Take
Evidence for Acetyl Tetrapeptide-5 is too preliminary to support a research protocol with confidence. All evidence comes from a single manufacturer-funded study on periorbital edema reduction. Independent replication does not exist. This compound should not be selected over better-evidenced cosmetic peptides.
- Best for
- Periorbital edema reduction research (manufacturer data only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established independent clinical protocol
Benefits and Evidence
- Under-Eye Puffiness Reduction: Level D, includes human evidence - Clinical evaluations sponsored by the manufacturer show measurable reduction in under-eye bag volume after 15-60 days of twice-daily application. Results were statistically significant vs. placebo.
- Anti-Glycation Activity: Level D, mostly non-human evidence - In vitro assays demonstrate inhibition of protein glycation, which is associated with vascular damage and increased fluid leakage in aging skin.
Side Effects and Warnings
- Generally well tolerated around the eyes
- Rare mild stinging in sensitive individuals
- Allergic contact reactions uncommon
- Limited independent peer-reviewed evidence
- Avoid direct contact with eyes
- Results are modest and may vary by individual
- Not a treatment for medical causes of periorbital edema
Research Dosage References
- <strong>Topical</strong> - 0.5-2% in eye cream or serum - Twice daily (morning and evening) - Specifically formulated for the periorbital area. Apply gently around the eye contour. Best results after 4-8 weeks of consistent use.
Mechanism of Action
Acetyl Tetrapeptide-5 reduces periorbital edema through multiple pathways: 1. Anti-glycation activity: Inhibits glycation of extracellular matrix proteins, which can increase vascular permeability and tissue water retention when damaged. 2. Vascular permeability reduction: Decreases the permeability of capillary walls, reducing fluid leakage into the periorbital interstitial space. 3. ACE inhibition: Acts as a weak angiotensin-converting enzyme inhibitor, potentially influencing local fluid balance. 4. Tissue drainage improvement: May enhance lymphatic drainage efficiency around the eyes by maintaining extracellular matrix integrity.
Legal Status
Cosmetic ingredient. Available over the counter in eye care products. Not regulated as a drug.
Primary Sources
- Efficacy of a tetrapeptide in reducing under-eye puffiness. Journal of Cosmetic Science, 2010.
- Anti-aging effects of cosmeceutical peptides on the periorbital area. Clinics in Dermatology, 2009.
Popular Questions
- Acetyl Tetrapeptide-5 Benefits: Evidence, Verdict, and Limits
- Acetyl Tetrapeptide-5 Side Effects: Safety Signals and Warnings
- Acetyl Tetrapeptide-5 Research Dosage: Published Protocol Reference
- Is Acetyl Tetrapeptide-5 Legit? Evidence Grade and Plain-English Verdict
- Acetyl Tetrapeptide-5 Legal Status: Approval, Research Use, and Regulatory Notes